Translational Advances in Urothelial Carcinoma: From Bench to Bedside

作者：Tomohiro Iwasawa, Takuya Tsujino, Shigehiro Tsukahara, Hiroshi Fukushima, Daisuke Ito, Eisuke Tomiyama, Fumihiko Urabe · 发表于：International Journal of Urology · 年份：2026 · DOI：10.1111/iju.70341 · 被引用次数：4 · 研究领域：Bladder and Urothelial Cancer Treatments、Single-cell and spatial transcriptomics、Extracellular vesicles in disease

Urothelial carcinoma (UC), encompassing both bladder cancer and upper tract UC, is a biologically heterogeneous malignancy that has long complicated patient stratification and therapeutic prediction. Recent genomic and transcriptomic analyses, however, have delineated reproducible molecular subtypes across non-muscle-invasive and muscle-invasive disease. These classification frameworks have refined biological understanding and improved both risk stratification and treatment selection. Emerging evidence also indicates that genomic alterations, such as FGFR3 mutations, may confer distinct immunologic phenotypes within specific transcriptomic contexts, thereby challenging prior assumptions. The advent of immune checkpoint inhibitors has transformed UC management, yet variable response rates underscore the complexity of the tumor microenvironment (TME). Single-cell and spatial analyses have identified immune-inflamed, -desert, and -excluded TME subtypes, with cancer-associated fibroblasts playing a key role in immune exclusion and therapeutic resistance. Liquid biopsy, particularly circulating tumor DNA, has demonstrated utility for real-time disease monitoring, minimal residual disease detection, and treatment stratification, as highlighted in trials such as IMvigor010 and IMvigor011. Urinary extracellular vesicles also represent promising non-invasive biomarkers, though further standardization is required. In addition, novel therapeutic strategies-including antibody-drug conjug...